In a study, those getting remdesivir showed a 62% lower risk of mortality
experienced lower mortality rates and better recovery times compared to those not getting the treatment.
The researchers compared 312 people hospitalized for COVID-19 and who received remdesivir to 818 people with similarly severe cases who were treated with standard of care, but did not need mechanical ventilation to breathe. Compared to the people in the latter group, those getting remdesivir showed a 62% lower risk of mortality during the study period. Furthermore, about 75% of patients receiving remdesivir recovered by day 14 after hospitalization, compared to 59% of those not getting the drug.
The analysis did not follow the rigorous gold standard of comparing an experimental treatment group to a control group within the same study, a method that ensures the two groups are similar as possible and better accounts for potentially confounding factors. A previous remdesivir study that met such criteria, conducted by the National institute of Allergy and Infectious Diseases and reported in late April,that people taking remdesivir had a shorter recovery time.
Gilead’s analysis is the next-best thing to a randomized placebo-controlled trial, and the company’s scientists acknowledge that more studies are needed to confirm the reduction in mortality. “To address the urgency of the continuing pandemic, we are sharing data with the research community as quickly as possible with the goal of providing transparent and timely updates on new developments with remdesivir,” Gilead Sciences Chief Medical Officer Merdad Parsey said in a statement.
Gilead also reported additional data showing that remdesivir provided similar benefit to people of racial and ethnic groups that seem to be
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Gilead begins testing inhalable form of remdesivir for COVID-19Gilead Sciences Inc said on Wednesday it has started an early-stage study of its antiviral COVID-19 treatment remdesivir that can be inhaled, for use outside of hospitals.
Read more »
Wall Street jumps with financials; Gilead data offsets virus fearsU.S. stocks rose on Friday as a positive analysis on Gilead Sciences Inc's antiviral drug to treat COVID-19 helped to soothe investor worries over a record rise in coronavirus cases in the United States, and as financial shares surged.
Read more »
Gilead Testing Inhaled Form Of Remdesivir That Could Be Used To Treat Covid-19 Outside HospitalGilead is launching a phase 1 clinical trial of an inhaled version of remdesivir, a drug used to treat Covid-19, that could be administered to patients outside of the hospital
Read more »
After Push From Experts, World Health Organization Says It's Possible COVID-19 Spreads By AirAfter Push From Experts, World Health Organization Says It’s Possible COVID-19 Spreads By Air
Read more »
Op-Ed: My research team makes COVID-19 death projections. Here's why our forecasts often changeMy team at the University of Washington makes COVID-19 death projections, which change as more information becomes available.
Read more »
New York governor to send remdesivir to Florida to assist with their Covid-19 battleNew York state will send the drug remdesivir to Florida to help the state fight the resurgence of Covid-19 cases, a statement from Gov. Andrew Cuomo’s office said
Read more »